Dr. Bendell on the Treatment of Microsatellite Stable Patients With CRC

Johanna C. Bendell, MD
Published: Tuesday, Nov 28, 2017



Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable (MSS).

Bendell says that 95% of patients with metastatic CRC are not microsatellite high, and treatments for them must be developed. Preliminary results of combinations with immunotherapy have shown promising response rates.

The combination of the PD-1 inhibitor atezolizumab (Tecentriq) with the MEK inhibitor cobimetinib (Cotellic) showed impressive preliminary results, and the combination has now moved into a randomized phase III global study.
 


Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable (MSS).

Bendell says that 95% of patients with metastatic CRC are not microsatellite high, and treatments for them must be developed. Preliminary results of combinations with immunotherapy have shown promising response rates.

The combination of the PD-1 inhibitor atezolizumab (Tecentriq) with the MEK inhibitor cobimetinib (Cotellic) showed impressive preliminary results, and the combination has now moved into a randomized phase III global study.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x